Catalyst
Slingshot members are tracking this event:
SAGE Expected to Begin Phase 1 Trial in H1 2017 Evaluating SAGE-718 in Cerebrosterol Deficit Disorders, Anti-NMDA Receptor Encephalitis, and NMDA Hypofunction
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SAGE |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 27, 2017
Occurred Source:
http://investor.sagerx.com/releasedetail.cfm?ReleaseID=1023207
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Sage-718, Phase 1, Nmda Modulator, Oxysterol, Cerebrosterol Deficit Disorders, Anti-nmda Receptor Encephalitis, Nmda Hypofunction
